Basic Information
RNALocate ID: | RLID:01001469 |
RNA Symbol: | hsa-miR-106a-5p |
Localization: | Cytoplasm |
RNA Information
RNA Name: | hsa-miR-106a |
RNA ID: | miRBase:MIMAT0000103 |
RNA Category: | miRNA |
Species: | Homo sapiens |
Localization Information
PubMed ID: | 21695135 |
Tissue/Cell Line: | Cell line (HeLa) |
Method: | Microarray |
Heatmap showing the 57 miRNAs differentially expressed in HeLa cells from mitochondrial and cytosolic RNA. Three independent microarray profiling experiments (microarray n1, n2 and n3) are shown and reproducibly revealed 13 miRNAs enriched in mitochondrial RNA. Originally published in PLoS One. Bandiera S, et al, 2011. Reproduced under the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) |
|
Description: | While 44 miRNAs showed a greater enrichment in the cytosolic Hy3-labeled RNA fraction, 13 miRNAs were significantly and reproducibly enriched in the mitochondrial Hy5-labeled RNA sample (ranging from 1.5- to 56-fold), namely hsa-miR-1973, hsa-miR-1275, hsa-miR-494, hsa-miR-513a-5p, hsa-miR-1246, hsa-miR-328, hsa-miR-1908, hsa-miR-1972, hsa-miR-1974, hsa-miR-1977, hsa-miR-638, hsa-miR-1978 and hsa-miR-1201 (Figure 5A). Data are collected from Figure 5. |
Other Subcellular Localization
RNALocate ID | Localization | Tissue/Cell line | PubMed ID |
RLID:01001467 | Cytoplasm | Nasopharyngeal carcinoma cells | 20498841 |
RLID:01001468 | Cytoplasm | Neural progenitor cells | 21363885 |
RLID:01001470 | Cytoplasm | Breast adenocarcinoma cells (MCF-7)|Cervical adenocarcinoma cells (HeLa) | 24918059 |
RLID:01001471 | Mitochondrion | Myotube | 27396686 |
RLID:01001472 | Mitochondrion | Skeletal muscle cells | 27563705 |
RLID:01001473 | Mitochondrion | Skeletal muscle myoblasts | 21637849 |
RLID:01001474 | Mitochondrion | Cell line (HEK-293|HeLa) | 22984580 |
RLID:01001475 | Nucleus | Breast adenocarcinoma cells (MCF-7)|Cervical adenocarcinoma cells (HeLa) | 24918059 |
RLID:01001476 | Nucleolus | Breast adenocarcinoma cells (MCF-7)|Cervical adenocarcinoma cells (HeLa) | 24918059 |
RLID:01001477 | Nucleus | Nasopharyngeal carcinoma cells | 20498841 |
RLID:11001035 | Apoptotic body | Human umbilical vein endothelial cells | 19996457 |
RLID:11001036 | Exosome | Sera | 24978137 |
RLID:11001037 | Exosome | Plasma | 19289371 |
RLID:11001038 | Exosome | Breast milk | 22211110 |
RLID:11001039 | Exosome | Brain tissue | 23382797 |
RLID:11001040 | Exosome | Plasma | 23663360 |
RLID:11001041 | Exosome | Human mast cell line (HMC-1) | 24009880 |
RLID:11001042 | Exosome | Colon cancer cell line (LIM1863) | 25330373 |
RLID:11001043 | Exosome | Serum | 25349172 |
RLID:11001044 | Microvesicle | Seminal plasma | 23539611 |
RLID:11001045 | Microvesicle | Follicular fluid | 23666971 |
RLID-D:11000302 | Microvesicle | Fibroblasts|Mesenchymal stem cells | |
RLID-D:11001161 | Exosome | Breast milk|Cell lines|Epididymal epithelial cells|Osteoblast|Plasma|Primary glioblastoma neurosphere cells|Primary keratinocyte|Saliva|Serum|Urine |
ncRNA Disease Information
Resource | RNA Symbol | Disease | Link |
MNDR | hsa-miR-106a-5p | Diffuse large b cell lymphoma | MNDR-E-MI-03360 |
MNDR | hsa-miR-106a-5p | Splenic marginal zone lymphoma | MNDR-E-MI-03361 |
MNDR | hsa-miR-106a-5p | Multiple sclerosis chronic progressive | MNDR-E-MI-03362 |
MNDR | hsa-miR-106a-5p | Oral squamous cell carcinoma | MNDR-E-MI-03363 |
MNDR | hsa-miR-106a-5p | Follicular cleaved lymphoma | MNDR-E-MI-03364 |
MNDR | hsa-miR-106a-5p | Medulloblastoma | MNDR-E-MI-03365 |
MNDR | hsa-miR-106a-5p | Small intestinal neuroendocrine tumor | MNDR-E-MI-03366 |
MNDR | hsa-miR-106a-5p | High-grade serous ovarian carcinoma | MNDR-E-MI-03367 |
MNDR | hsa-miR-106a-5p | Ovarian clear cell carcinoma | MNDR-E-MI-03368 |
MNDR | hsa-miR-106a-5p | Uterine corpus endometrial carcinoma | MNDR-E-MI-03369 |
MNDR | hsa-miR-106a-5p | Lymphoma | MNDR-E-MI-03370 |
MNDR | hsa-miR-106a-5p | Lymphoma non-hodgkin | MNDR-E-MI-03371 |
MNDR | hsa-miR-106a-5p | Estrogen-receptor positive breast cancer | MNDR-E-MI-03372 |
MNDR | hsa-miR-106a-5p | Estrogen-receptor negative breast cancer | MNDR-E-MI-03373 |
MNDR | hsa-miR-106a-5p | Progesterone-receptor positive breast cancer | MNDR-E-MI-03374 |
MNDR | hsa-miR-106a-5p | Progesterone-receptor negative breast cancer | MNDR-E-MI-03375 |
MNDR | hsa-miR-106a-5p | Her2-receptor positive breast cancer | MNDR-E-MI-03376 |
MNDR | hsa-miR-106a-5p | Breast cancer luminal | MNDR-E-MI-03377 |
MNDR | hsa-miR-106a-5p | Precursor cell lymphoblastic leukemia-lymphoma | MNDR-E-MI-03378 |
MNDR | hsa-miR-106a-5p | B cell acute lymphoblastic leukemia | MNDR-E-MI-03379 |
MNDR | hsa-miR-106a-5p | Small intestine cancer | MNDR-E-MI-03380 |
MNDR | hsa-miR-106a-5p | Prostate cancer | MNDR-E-MI-03381 |
MNDR | hsa-miR-106a-5p | Gastric cancer | MNDR-E-MI-03382 |
MNDR | hsa-miR-106a-5p | Gastric lymphoma | MNDR-E-MI-03383 |
MNDR | hsa-miR-106a-5p | Alzheimer disease | MNDR-E-MI-03384 |
MNDR | hsa-miR-106a-5p | Dysautonomia familial | MNDR-E-MI-03385 |
MNDR | hsa-miR-106a-5p | Leukemia | MNDR-E-MI-03386 |
MNDR | hsa-miR-106a-5p | Huntington disease | MNDR-E-MI-03387 |
MNDR | hsa-miR-106a-5p | Chorea | MNDR-E-MI-03388 |
MNDR | hsa-miR-106a-5p | Carotid stenosis | MNDR-E-MI-03389 |
MNDR | hsa-miR-106a-5p | Lung cancer | MNDR-E-MI-03390 |
MNDR | hsa-miR-106a-5p | Fragile x syndrome | MNDR-E-MI-03391 |
MNDR | hsa-miR-106a-5p | Parkinson disease | MNDR-E-MI-03392 |
MNDR | hsa-miR-106a-5p | Basal-like breast cancer | MNDR-E-MI-03393 |
MNDR | hsa-miR-106a-5p | Pancreatic cancer | MNDR-E-MI-03394 |
MNDR | hsa-miR-106a-5p | Melanoma | MNDR-E-MI-03395 |
MNDR | hsa-miR-106a-5p | Lesch-nyhan syndrome | MNDR-E-MI-03396 |
MNDR | hsa-miR-106a-5p | Rectum adenocarcinoma | MNDR-E-MI-03397 |
MNDR | hsa-miR-106a-5p | Hepatitis B | MNDR-E-MI-03398 |
MNDR | hsa-miR-106a-5p | Epithelial ovarian cancer | MNDR-E-MI-03399 |
MNDR | hsa-miR-106a-5p | Nephroblastoma | MNDR-E-MI-03400 |
MNDR | hsa-miR-106a-5p | Colon cancer | MNDR-E-MI-03401 |
MNDR | hsa-miR-106a-5p | Ischemic attack transient | MNDR-E-MI-03402 |
MNDR | hsa-miR-106a-5p | Colon adenocarcinoma | MNDR-E-MI-03403 |
MNDR | hsa-miR-106a-5p | Multiple sclerosis | MNDR-E-MI-03404 |
MNDR | hsa-miR-106a-5p | Multiple sclerosis relapsing-remitting | MNDR-E-MI-03405 |
MNDR | hsa-miR-106a-5p | Familial ovarian cancer | MNDR-E-MI-03406 |
MNDR | hsa-miR-106a-5p | Prostate adenocarcinoma | MNDR-E-MI-03407 |
MNDR | hsa-miR-106a-5p | Kidney cancer | MNDR-E-MI-03408 |
MNDR | hsa-miR-106a-5p | Carcinoma ductal breast | MNDR-E-MI-03409 |
MNDR | hsa-miR-106a-5p | Glioblastoma | MNDR-E-MI-03410 |
MNDR | hsa-miR-106a-5p | Astrocytoma | MNDR-E-MI-03411 |
MNDR | hsa-miR-106a-5p | Glioma | MNDR-E-MI-03412 |
MNDR | hsa-miR-106a-5p | Amyotrophic lateral sclerosis | MNDR-E-MI-03413 |
MNDR | hsa-miR-106a-5p | Epilepsy temporal lobe | MNDR-E-MI-03414 |
MNDR | hsa-miR-106a-5p | Osteosarcoma | MNDR-E-MI-03415 |
MNDR | hsa-miR-106a-5p | Liposarcoma | MNDR-E-MI-03416 |
MNDR | hsa-miR-106a-5p | Meningioma | MNDR-E-MI-03417 |
MNDR | hsa-miR-106a-5p | Liver cancer | MNDR-E-MI-03418 |
MNDR | hsa-miR-106a-5p | Cervical adenocarcinoma | MNDR-E-MI-03419 |
MNDR | hsa-miR-106a-5p | Gastric adenocarcinoma | MNDR-E-MI-03420 |
MNDR | hsa-miR-106a-5p | Cervical squamous cell carcinoma | MNDR-E-MI-03421 |
MNDR | hsa-miR-106a-5p | Lung squamous cell carcinoma | MNDR-E-MI-03422 |
MNDR | hsa-miR-106a-5p | Carcinoma lung non-small-cell | MNDR-E-MI-03423 |
MNDR | hsa-miR-106a-5p | Lung adenocarcinoma | MNDR-E-MI-03424 |
MNDR | hsa-miR-106a-5p | Thyroid carcinoma | MNDR-E-MI-03425 |
MNDR | hsa-miR-106a-5p | Ovarian carcinoma | MNDR-E-MI-03426 |
MNDR | hsa-miR-106a-5p | Bladder urothelial carcinoma | MNDR-E-MI-03427 |
MNDR | hsa-miR-106a-5p | Pancreatic adenocarcinoma | MNDR-E-MI-03428 |
MNDR | hsa-miR-106a-5p | Carcinoma renal cell | MNDR-E-MI-03429 |
MNDR | hsa-miR-106a-5p | Papillary renal cell carcinoma | MNDR-E-MI-03430 |
MNDR | hsa-miR-106a-5p | Clear cell renal cell cancer | MNDR-E-MI-03431 |
MNDR | hsa-miR-106a-5p | Biliary tract cancer | MNDR-E-MI-03432 |
MNDR | hsa-miR-106a-5p | Cholangiocarcinoma | MNDR-E-MI-03433 |
MNDR | hsa-miR-106a-5p | Esophageal cancer | MNDR-E-MI-03434 |
MNDR | hsa-miR-106a-5p | Lung small cell carcinoma | MNDR-E-MI-03435 |
MNDR | hsa-miR-106a-5p | Head and neck squamous cell carcinoma | MNDR-E-MI-03436 |
MNDR | hsa-miR-106a-5p | Testicular germ cell cancer | MNDR-E-MI-03437 |
MNDR | hsa-miR-106a-5p | T acute lymphoblastic leukemia | MNDR-E-MI-03438 |
MNDR | hsa-miR-106a-5p | Acute t cell leukemia | MNDR-E-MI-03439 |
MNDR | hsa-miR-106a-5p | Acute heart failure | MNDR-E-MI-03440 |
MNDR | hsa-miR-106a-5p | Aortic valve disease | MNDR-E-MI-03441 |
MNDR | hsa-miR-106a-5p | Adenoma | MNDR-E-MI-03442 |
MNDR | hsa-miR-106a-5p | Breast invasive carcinoma | MNDR-E-MI-03443 |
MNDR | hsa-miR-106a-5p | Hepatocellular carcinoma | MNDR-E-MI-03444 |
MNDR | hsa-miR-106a-5p | Embryonal cancer | MNDR-E-MI-03445 |
MNDR | hsa-miR-106a-5p | Familiar ovarian carcinoma | MNDR-E-MI-03446 |
MNDR | hsa-miR-106a-5p | B-cell lymphoma | MNDR-E-MI-03447 |
MNDR | hsa-miR-106a-5p | T-cell leukemia | MNDR-E-MI-03448 |
MNDR | hsa-miR-106a-5p | Neuroblastoma | MNDR-E-MI-03449 |
MNDR | hsa-miR-106a-5p | Burkitt lymphoma | MNDR-E-MI-03450 |
MNDR | hsa-miR-106a-5p | Psoriasis | MNDR-E-MI-03451 |
MNDR | hsa-miR-106a-5p | Acute myelocytic leukemia | MNDR-E-MI-03452 |
MNDR | hsa-miR-106a-5p | Colorectal cancer | MNDR-E-MI-03453 |
MNDR | hsa-miR-106a-5p | Multiple myeloma | MNDR-E-MI-03454 |
MNDR | hsa-miR-106a-5p | Ependymoma | MNDR-E-MI-03455 |
MNDR | hsa-miR-106a-5p | Prostatic neoplasms | MNDR-E-MI-03456 |
MNDR | hsa-miR-106a-5p | Pseudorabies | MNDR-E-MI-03457 |
MNDR | hsa-miR-106a-5p | Hypersomnolence idiopathic | MNDR-E-MI-03458 |
MNDR | hsa-miR-106a-5p | Arsenic poisoning | MNDR-E-MI-03459 |
MNDR | hsa-miR-106a-5p | Stroke lacunar | MNDR-E-MI-03460 |
MNDR | hsa-miR-106a-5p | Duke C | MNDR-E-MI-03461 |
RNA Interaction Information
Resource | RNA Symbol | Species | Link | RNALocate ID |
RNAInter | ABHD2 | Homo sapiens | RR00026071 |
TOP